Project Grant R01CA294563

Award Date 7/8/24
Completion Date 6/30/29
Dollars Obligated $1.5M
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) provides $627,474 to support research aimed at improving the detection, diagnosis, and understanding of prostate cancer progression. The key objectives of this 5-year project are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies that can detect the emergence of treatment-resistant neuroendocrine...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
The National Cancer Institute (NCI) awarded Emory University a $1,082,472 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to determine the molecular mechanisms underlying the progression of prostate adenocarcinoma (ADPC) to the lethal neuroendocrine prostate cancer (NEPC) subtype. The 5-year project aims to investigate how the transcription factor FOXA2 interacts with NKX2-1 to drive this luminal-to-neuroendocrine transdifferentiation process, including examining the role...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $415,902 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key objectives are to: Determine if expression of the FOXA2 transcription factor can drive luminal prostate cancer cells into a multilineage transition state. This will involve assessing FOXA2 chromatin binding...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The key objectives are to: Determine the mechanisms by which transcriptional regulators modulate prostate cancer cell differentiation and hallmarks. Understand how these transcriptional regulators are upregulated in human prostate tumors and their association...
This federal Project Grant award for $710,980.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research aimed at defining the molecular mechanisms and therapeutic potential of targeting the SPOP ubiquitin signaling pathway in prostate cancer. Key objectives include: Elucidating the role of the SPOP pathway regulator G3BP1 in driving prostate tumorigenesis and evaluating the ability to target this upstream axis. Establishing the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,133 to The Trustees of Columbia University in the City of New York to investigate the nuclear and non-nuclear functions of the NKX3.1 gene in suppressing prostate cancer progression, particularly in the context of aging-related mitochondrial dysfunction. The key objectives are to: 1) Examine how the nuclear and mitochondrial roles of NKX3.1 contribute to prostate cancer...

INVESTIGATING THE IMPACT OF CHROMOSOMAL INSTABILITY ON PROSTATE CANCER AGGRESSIVENESS - PROJECT SUMMARY PROSTATE CANCER (PC) IS A LEADING CAUSE OF MALE CANCER-RELATED DEATHS. ONCE DISSEMINATED PC IS INCURABLE AS IT GRADUALLY PROGRESSES TO ALL THERAPEUTIC OPTIONS. THE MECHANISMS UNDERLYING AGGRESSIVE FEATURES AND LETHALITY OF METASTATIC PC REMAIN AN UNMET CLINICAL NEED. WE AND OTHERS HAVE REPORTED THAT METASTATIC PC DISPLAYS THE HIGHEST LEVELS OF CHROMOSOMAL INSTABILITY (CIN), AND WE HAVE SHOWN THAT TRANSCRIPTIONAL REPROGRAMMING ALLOWS PC CIN-ADAPTATION AND SURVIVAL IN ADVANCED DISEASE. YET, THE MOLECULAR UNDERPINNINGS OF CIN IMPACT ON PC REMAIN POORLY UNDERSTOOD. USING GENETIC, PROTEOMIC, EPIGENOMICS AND HIGH-RESOLUTION MICROSCOPY, WE FOUND THAT CIN IS LINKED TO TRANSCRIPTIONAL REWIRING AND BOOKMARKING SUGGESTING A ROLE OF CIN IN CELL REPROGRAMMING IN LETHAL PC. HIGH CIN PC REMAINS HIGHLY DEPENDENT ON MITOTIC FIDELITY PROGRAMS LIKE THE ONES CONTROLLED BY MASTL KINASE TO RESTRAIN LETHAL CATASTROPHIC CIN LEVELS. WE FIND THAT MASTL REGULATES NEW LATE MITOTIC PROCESSES INVOLVED IN CENTROSOME BIOLOGY AND CYTOKINESIS IN PC CELLS. HOWEVER, THE SUBSTRATES AND EFFECTORS BY WHICH MASTL REGULATE THESE FUNCTIONS REMAIN UNKNOWN. FINALLY, OUR IN VIVO DATA STRONGLY SUGGEST A RELEVANT ROLE OF CIN IMPACTING ANTI- TUMOR IMMUNITY IN PC. IN THIS APPLICATION WE WILL USE UNIQUE GENETIC MODELS TO IDENTIFY THE SUBSTRATES AND COFACTORS BY WHICH MASTL KINASE REGULATES NEW FUNCTIONS IN HIGH CIN PC (AIM 1). WE WILL INVESTIGATE THE MOLECULES AND MECHANISMS UNDERLYING CIN-INDUCED TRANSCRIPTIONAL REPROGRAMMING AND GENE BOOKMARKING IN PC (AIM 2) AND WILL EXPLORE THE TUMOR IMMUNE CELL INTRINSIC AND EXTRINSIC MECHANISMS TRIGGERED BY CIN IN PC THAT MAY ENHANCE IMMUNOTHERAPY EFFICACY (AIM 3). THROUGH THESE STUDIES WE WILL MECHANISTICALLY UNCOVER NOVEL ASPECTS OF CIN CONSEQUENCES FOR PC AND MAY IDENTIFY NEW POTENTIAL TREATMENT STRATEGIES FOR THIS LETHAL DISEASE.

Posted 7/5/24, 12:00 AM